Biodisposition of the Promising JNK Inhibitor IQ-1 and its Metabolite in Rats Following Single Oral Administration
Pharmaceutical Sciences · 31.10.2026 · 32 (4) · 611-622
DOI: 10.34172/ps.43665 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutical Sciences, online erschienen am 29.07.2026. Verfasst von Galina A. Frelikh und 5 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben.
Abstract (Originalsprache)
Introduction
The JNK inhibitor 11H-indeno[1,2-b]quinoxalin-11-one oxime (IQ-1) and its sodium salt exhibit antioxidant, hemorheological, endothelium-protective, anti-inflammatory, neuroprotective, and cardioprotective properties; however, no published reports describe their tissue distribution. We investigated the biodisposition of IQ-1 and its major metabolite, 11H-indeno[1,2-b]quinoxalin-11-one (IQ-18), in Wistar rats after a single oral 50 mg/kg dose of IQ-1.
Methods
Male adult Wistar rats (230–260 g) received IQ-1 orally (50 mg/kg). To investigate plasma pharmacokinetics and tissue distribution of IQ-1 and its metabolite IQ-18 in rats, arterial blood was collected from the carotid artery, and tissue samples (liver, kidney, heart, brain, lung, spleen, skeletal muscle, adipose tissue, and duodenum) were harvested following oral administration of 50 mg/kg IQ-1. Mesenteric lymph, bile, and blood from the portal vein and inferior vena cava were also obtained post-dose to clarify the absorption routes and metabolic sites of IQ-1. Chromatographic separation was carried out on an EC Nucleodur C8 ec LC column (150×4.6 mm, 5 µm; Macherey-Nagel, Germany). IQ-1 and IQ-18 were quantified by validated LC-MS/MS method using a LC-20 Prominence system (Shimadzu) and a mass spectrometer 3200 QTRAP (AB Sciex). Analyst 1.6 and MultiQuant 2.1 (AB Sciex) handled data acquisition and analysis. Non-compartmental pharmacokinetic parameters were calculated with WinNonlin 5.2 (Pharsight). Statistics (Mann–Whitney U test; P
Zitieren
APA
Frelikh, G. A., Yanovskaya, E. A., Lakeev, A. P., Chernysheva, G. A., Smolyakova, V. I., & Khlebnikov, A. I. (2026). Biodisposition of the Promising JNK Inhibitor IQ-1 and its Metabolite in Rats Following Single Oral Administration. Pharmaceutical Sciences, 32(4), 611-622. https://doi.org/10.34172/ps.43665
Vancouver
Frelikh GA, Yanovskaya EA, Lakeev AP, Chernysheva GA, Smolyakova VI, Khlebnikov AI. Biodisposition of the Promising JNK Inhibitor IQ-1 and its Metabolite in Rats Following Single Oral Administration. Pharmaceutical Sciences. 2026;32(4):611-622. doi:10.34172/ps.43665
BibTeX
@article{Frelikh2026,
author = {Frelikh, Galina A. and Yanovskaya, Elena A. and Lakeev, Alexander P. and Chernysheva, Galina A. and Smolyakova, Vera I. and Khlebnikov, Andrei I.},
title = {Biodisposition of the Promising JNK Inhibitor IQ-1 and its Metabolite in Rats Following Single Oral Administration},
journal = {Pharmaceutical Sciences},
year = {2026},
volume = {32},
number = {4},
pages = {611--622},
doi = {10.34172/ps.43665}
}
EUVIMED